In today’s briefing:
- Hansoh Pharmaceutical (3692 HK): Innovative Drugs Drive 2024 Performance; Outlook Is Positive
- ANVS: CEO on Taking Treatments of Neurodegenerative Diseases to the Next Level
- How BioNTech’s Growing Oncology Pipeline Could Reshape Its Future!
- ABEO: Countdown to PDUFA Date of April 29, 2025
- Legend Biotech: An Insight Into Its Manufacturing Capacity Expansion & Major Growth Levers!
- MIRA: Expands Pipeline and Increases Capital
- Pre-IPO Duality Biotherapeutics (PHIP Updates) – Some Points Worth the Attention
Hansoh Pharmaceutical (3692 HK): Innovative Drugs Drive 2024 Performance; Outlook Is Positive
- Hansoh Pharmaceutical Group (3692 HK) reported 33% YoY net profit growth to RMB4.4B on 21% YoY revenue growth to RMB12.3B in 2024. Oncology revenue jumped 32% YoY to RMB8.1B.
- Revenue from innovative drugs zoomed 38% YoY to RMB9.5B and its proportion to total revenue increased to 77.3% in 2024 from 67.9% in 2023.
- In 2024, three key innovative drug candidates entered the phase 3 clinical stage for the first time. Hansoh will continue to focus on R&D of innovative drugs and internationalization strategy.
ANVS: CEO on Taking Treatments of Neurodegenerative Diseases to the Next Level
- Annovis Bio is a late-stage clinical drug platform company that develops novel disease-modifying therapies for neurodegenerative diseases.
- The company recently initiated a Phase 3 study in its lead small molecule candidate Buntanetap, which targets early-stage Alzheimer’s.
- Annovis completed a Phase 3 study of Buntanetap for Parkinson’s and is expected to meet with the FDA in 2Q25 to determine the path forward for the program.
How BioNTech’s Growing Oncology Pipeline Could Reshape Its Future!
- BioNTech, a pioneering biopharmaceutical company, revealed their fourth quarter and full year financial results for 2024, along with strategic priorities moving into 2025.
- The company remains steadfast in its mission to leverage its immunotherapy and architectural prowess to tackle diseases, especially cancer and infectious diseases like COVID-19.
- In 2024, BioNTech reported revenues of approximately EUR 2.8 billion, aligning with the midpoint of its guidance, although this represents a decline from the previous year, attributed to reduced COVID-19 vaccine demand.
ABEO: Countdown to PDUFA Date of April 29, 2025
- On March 20, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the fourth quarter and full year of 2024 and provided a business update.
- Preparations continue for the potential approval of prademagene zamikeracel (pz-cel), which has a PDUFA date of April 29, 2025.
- Abeona disclosed that it received draft prescribing information on the label for pz-cel, which was in-line with company expectations.
Legend Biotech: An Insight Into Its Manufacturing Capacity Expansion & Major Growth Levers!
- Legend Biotech’s recent financial disclosures and strategic updates present a multifaceted view of the company’s performance and outlook.
- The firm has made significant strides with its CARVYKTI therapy, a CAR-T treatment for multiple myeloma, suggesting a robust growth trajectory influenced by several critical factors.
- Positively, Legend Biotech is experiencing strong demand for CARVYKTI, with net trade sales reaching approximately $334 million in the fourth quarter of 2024.
MIRA: Expands Pipeline and Increases Capital
- MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
Pre-IPO Duality Biotherapeutics (PHIP Updates) – Some Points Worth the Attention
- Since DB-1303 has no advantage in clinical data in front of competing products, the commercialization outlook is gloomy. The priority for DB-1311 is to verify the druggability of this target.
- Considering that the current capital market has become more and more rational toward innovative drug/biotech companies, the absence of commercialized products of Duality will obviously affect valuation expectations.
- The post-money valuation after Series B+ financing is about US$270 million (or about RMB2 billion), which is not expensive, and there is a chance to obtain valuation premium after IPO.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
Unlock all research summaries